Chemoinformaics analysis of N-Methyl-L-Anatabine
| Molecular Weight | 160.22 | nRot | 1 |
| Heavy Atom Molecular Weight | 148.124 | nRig | 12 |
| Exact Molecular Weight | 160.1 | nRing | 2 |
| Solubility: LogS | 0.438 | nHRing | 2 |
| Solubility: LogP | 0.964 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 24 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 26.9015 |
| nHD | 1 | BPOL | 13.7485 |
| QED | 0.632 |
| Synth | 3.31 |
| Natural Product Likeliness | 0.467 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.008 |
| HIA | 0.011 |
| CACO-2 | -4.309 |
| MDCK | 0.00000521 |
| BBB | 0.927 |
| PPB | 0.17719 |
| VDSS | 2.724 |
| FU | 0.815203 |
| CYP1A2-inh | 0.131 |
| CYP1A2-sub | 0.751 |
| CYP2c19-inh | 0.173 |
| CYP2c19-sub | 0.775 |
| CYP2c9-inh | 0.015 |
| CYP2c9-sub | 0.765 |
| CYP2d6-inh | 0.178 |
| CYP2d6-sub | 0.882 |
| CYP3a4-inh | 0.318 |
| CYP3a4-sub | 0.295 |
| CL | 10.986 |
| T12 | 0.559 |
| hERG | 0.029 |
| Ames | 0.013 |
| ROA | 0.743 |
| SkinSen | 0.889 |
| Carcinogencity | 0.283 |
| EI | 0.022 |
| Respiratory | 0.8 |
| NR-Aromatase | 0.008 |
| Antiviral | No |
| Prediction | 0.879865 |